Samsung Bioepis Toasts First Bevacizumab Biosimilar In Korea

Onbevzi Rival To Avastin Launched By Partner Boryung Pharmaceutical

 
• By Dean Rudge

Samsung Bioepis has expanded its portfolio of biosimilar products in its domestic South Korea, with the launch of bevacizumab via partner Boryung Pharmaceutical.

koreamarket
Samsung Bioepis also has a partnership with Yuhan • Source: Alamy

More from Biosimilars

More from Products